Pfizer Is Worst-Performing US Large-Cap Pharma Stock This Year, Its Investment Case Is Complex Yet Rewarding
Credit Suisse has initiated coverage on Pfizer Inc (NYSE:PFE) with an Outperform rating and a price target of $55. The analyst…
Analyst Expects Derisking Required Ahead Of Patent Expiry For This Large Pharma/MedTech Stock
Credit Suisse has initiated coverage on Johnson & Johnson (NYSE:JNJ) with a Neutral rating and a price target of $170. The…
Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth
Credit Suisse has initiated coverage on Amgen Inc (NYSE:AMGN) with an Underperform rating and a price target of $240. The analysts say…
Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers
Credit Suisse has initiated coverage on Bristol-Myers Squibb Co (NYSE:BMY) with a Neutral rating and a price target of $78. The analysts…
Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth
Credit Suisse has initiated coverage on AbbVie Inc (NYSE:ABBV) with an Outperform rating and a price target of $170. AbbVie stands on…
Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage
Credit Suisse has initiated coverage on Eli Lilly And Co (NYSE:LLY) with an Outperform rating and a price target of $395. Management…
Credit Suisse Believes In This Pharma Giant’s Low Risk Growth Against Uncertain Backdrop
Credit Suisse has initiated coverage on Merck & Co Inc (NYSE:MRK) with an Outperform rating and a price target of $120. The…
Canada Approves Novavax’s COVID-19 Vaccine As Booster In Adults
Health Canada has granted expanded approval to Novavax Inc's (NASDAQ: NVAX) Nuvaxovid (COVID-19 Vaccine as a homologous booster in adults aged 18 and older.
Pfizer/BioNTech’s Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced results from an analysis examining the immune response induced by their Omicron BA.4/BA.5-tailored bivalent COVID-19…
